BioVie Inc

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) investors concerning the Company's possible violations of federal securities laws. On November 8, 2023, BioVie disclosed that, for the Phase 3 clinical trial of its Alzheimer's treatment, NE3107, the Company had “uncovered what appears to be potential scientific misconduct and significant non-compliance with [Good Clinical Practices (“GCPs.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of BioVie Inc. (BIVI) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / January 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On November 8, 2023, BioVie disclosed that, for the Phase 3 clinical trial of its Alzheimer's treatment, NE3107, the Company had “uncovered what appears to be potential scientific mi.

The Law Offices of Frank R. Cruz Announces Investigation of BioVie Inc. (BIVI) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / January 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses In Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $BIVI #ClassActionLawsuit--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Nevada on behalf of those who acquired BioVie, Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) securities during the period of August 5, 2021 through November 29, 2023, inclusive (“the Class Period”). Investors have until March 19, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. On November 8, 2023, the Co.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of BioVie, Inc. (BIVI) Investors

NEW YORK , Jan. 22, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and November 29, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioVie Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BIVI

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of BioVie Inc. (NASDAQ: BIVI) between August 5, 2021 and November 29, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 19, 2024. SO WHAT: If you purchased BioVie securities during the Class Period you.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioVie Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BIVI

LOS ANGELES, CA / ACCESSWIRE / January 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ: BIVI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses In Excess of $100,000 to Contact the Firm

bioAffinity Technologies Inc

ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January 5, at 7 p.m. Eastern Time (ET).

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

Genetic Technologies

ORLANDO, FL / ACCESSWIRE / December 29, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET).

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

NEW YORK, Dec. 24, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BioVie Inc. (NASDAQ: BIVI) resulting from allegations that BioVie may have issued materially misleading business information to the investing public. SO WHAT: If you purchased BioVie securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BIVI INVESTOR NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages BioVie Inc. Investors with Losses to Inquire About Securities Class Action Investigation - BIVI

Rail Vision Ltd

ORLANDO, FL / ACCESSWIRE / December 22, 2023 / RedChip Companies will air interviews with Rail Vision (NASDAQ:RVSN) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 23, at 7 p.m. Eastern Time (ET).

Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BioVie Inc. (NASDAQ: BIVI) resulting from allegations that BioVie may have issued materially misleading business information to the investing public. SO WHAT: If you purchased BioVie securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law.

ROSEN, A LONGSTANDING LAW FIRM, Encourages BioVie Inc. Investors to Inquire About Securities Class Action Investigation – BIVI

NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On BioVie Inc. - BIVI

The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

BioVie (NASDAQ: BIVI ) stock is falling on Wednesday after the company released data from a Phase 3 clinical trial of its Alzheimer's Disease treatment candidate NE3107. Unfortunately for investors in BIVI stock, that study failed to meet its primary endpoint of statistical significance.

Why Is BioVie (BIVI) Stock Down 63% Today?

BioVie Inc (NASDAQ:BIVI), the clinical-stage company specializing in drug therapies for neurological disorders, revealed new results from the Phase 3 trial of NE3107 in patients with mild to moderate Alzheimer's Disease (AD). The trial, initiated during the COVID-19 pandemic, enrolled 439 patients across 39 sites.

BioVie reports efficacy data from NE3107 Phase 3 trial for Alzheimer's Disease

Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active  and May Have Impact on Cognitive, Functional, and Biomarker Endpoints

BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer's Disease

Blinded Phase 3 data of NE3107 in Alzheimer's appear to indicate robust cognitive and biomarker efficacy. Market is significantly undervaluing the probability of a successful data unblinding expected shortly after Thanksgiving. Potential to be the first neurodegenerative biotech to show significant improvement in cognition Alzheimer's disease with suspected disease modification.

BioVie: Cautiously Optimistic Ahead Of Phase 3 Alzheimer's Data Unblinding

BioVie is set to report topline data from its Phase 3 trial in Alzheimer's disease, with a high likelihood of reaching statistical significance. Blinded data from the trial showed a reduction in amyloid burden and cognitive improvements in about 75% of patients. NE3107, BioVie's drug candidate, appears to show efficacy across all hallmarks of Alzheimer's disease, including aging.

BioVie: Upcoming Phase 3 Readout In Alzheimer's May Create Significant Value

BioVie Inc (NASDAQ:BIVI) has presented data from its Phase 2b trial evaluating the efficacy and safety of its drug candidate BIV201 for liver disease at The American Association for the Study of Liver Diseases – The Liver Meeting in Boston, Massachusetts. The company said the trial showed that BIV201 in combination with the standard of care in patients with refractory ascites due to cirrhosis was well tolerated with no major difference in treatment-emergent adverse events when compared to the standard of care alone.

BioVie presents positive safety data from Phase 2 liver disease trial

Data Show that BIV201 in Combination with Standard of Care (SOC) is Well Tolerated with No Major Difference in Treatment-Emergent Adverse Events (TEAEs) Compared to SOC Alone

BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023

ORLANDO, FL / ACCESSWIRE / November 10, 2023 / RedChip Companies will air interviews with DevvStream Holdings Inc. (CBOE:DESG)(OTCQB:DSTRF)(FSE:CQ0) and BioVie Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, November 11, at 7 p.m. Eastern Time (ET).

News for BioVie Inc Stock (BIVI)